MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Humanigen, Inc. - Common Stock (NQ:HGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humanigen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Why Did Humanigen's Stock Dump Today And What's Next? ↗
Humanigen Inc. (NASDAQ:HGEN) shares are trading sharply lo... 
Via Benzinga
News headline image
Mid-Day Market Update: Torrid Surges After Q2 Results; Humanigen Shares Slide ↗
Midway through trading Thursday, the Dow traded up 0.10% to 35,067.66 while the NASDAQ rose 0.20% to 15,316.45. The S&P also rose, gaining 0.04% to 4,516.10. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
Here's Why Humanigen Is Getting Hammered Today ↗
An attempt to earn authorization for lenzilumab hit a wall at the FDA. 
Via The Motley Fool
News headline image
35 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE:... 
Via Benzinga
Understanding Humanigen's Unusual Options Activity ↗
Humanigen (NASDAQ:HGEN) shares experienced unusual option... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 ↗
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Rise; Jobless Claims Fall To 310,000 ↗
Following the market opening Thursday, the Dow traded up 0.36% to 35,158.32 while the NASDAQ rose 0.41% to 15,348.81. The S&P also rose, gaining 0.26% to 4,525.59. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
Humanigen Stock Pummeled After FDA Rejects Its Experimental Covid Drug ↗
The Food and Drug Administration rejected Humanigen's experimental Covid treatment on Thursday, sending HGEN stock into a dive. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Soligenix (NASDAQ:SNGX) stock increased by 22.85% to $1.29 during Thursday's pre-market session. The company's market cap stands at $51.7 million. Cardiff... 
Via Benzinga
News headline image
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
News headline image
21 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Cardiff Oncology, Inc. (NASDAQ: CRDF) rose 17.3% to $8.27 in pre-market trading after the company announced new data from its Phase 1b/2 trial in KRAS-mutated metastatic... 
Via Benzinga
News headline image
See Why Humanigen Stock Is Plunging To 52-Week Low ↗
The FDA declined Humanigen Inc's (NASDAQ: HGEN) request for emergency use authorization (EUA) of its lenzilumab drug to treat newly hospitalized COVID-19... 
Via Benzinga
News headline image
FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients
From Humanigen, Inc.
Via Business Wire
News headline image
Analyzing Humanigen's Unusual Options Activity ↗
Humanigen (NASDAQ:HGEN) shares experienced unusual options activity on Monday. The stock price moved down to $16.48 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
News headline image
Humanigen Reports Second Quarter 2021 Financial Results
From Humanigen, Inc.
Via Business Wire
News headline image
I-Mab Stock Is Trading Lower After Unveiling Mid-Stage Trial Data Of Plonmarlimab In Hospitalized COVID-19 Patients ↗
I-Mab (NASDAQ: IMAB) has announced interim data from its Phase 2/3 study evaluating plonmarlimab (TJM2 or TJ003234) for cytokine release syndrome (CRS) in patients... 
Via Benzinga
News headline image
Humanigen's COVID-19 Candidate Shows 2.5 Fold Increase In Survival Without Ventilation ↗
Humanigen Inc (NASDAQ: HGEN) has announced an analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in hospitalized patients with COVID-19. Data... 
Via Benzinga
News headline image
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
From Humanigen, Inc.
Via Business Wire
News headline image
NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19
From Humanigen, Inc.
Via Business Wire
News headline image
Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab
From Humanigen, Inc.
Via Business Wire
News headline image
Unusual Options Activity Insight: Humanigen ↗
Shares of Humanigen (NASDAQ:HGEN) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved up to $16.85. Sentiment: BEARISH Option... 
Via Benzinga
News headline image
Humanigen Stock Jumps As Lenzilumab Application Is Under Review In UK For COVID-19 ↗
The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted for review Humanigen Inc's (NASDAQ: HGEN) marketing application seeking... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Galectin Therapeutics (NASDAQ:GALT) shares moved upwards by 47.46% to $4.07 during Friday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
News headline image
UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review
From Humanigen, Inc.
Via Business Wire
News headline image
Humanigen Inc. Added to Russell 3000(R) Index
Burlingame, California--(Newsfile Corp. - June 28, 2021) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing... 
Via Newsfile
Topics Derivatives Regulatory Compliance
News headline image
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)
From Humanigen, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021 ↗
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
News headline image
Why This COVID-19 Stock Is On Fire Right Now ↗
While vaccines and diagnostics have been the big winners in the space so far, Humanigen might make investors a lot of money with its drug to treat cytokine storms caused by COVID-19. 
Via The Motley Fool
News headline image
Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations
From Humanigen, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story